anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a prospective randomized control trial comparing three methods of treatment for acute DRUJ instability with or without concomitant distal radius fracture. Upon determination of residual DRUJ instability either preoperatively or intraoperatively after distal radius fracture fixation, patients will be randomized into one of the three treatment arms of the study: nonoperative treatment with immobilization, percutaneous DRUJ fixation with Kirschner wires, and open anatomic foveal repair of Triangular fibrocartilage complex TFCC ligaments with suture. Those patients undergoing Kirschner wire fixation will have their pins pulled in the clinic setting six weeks postoperatively. Outcomes will be assessed at follow up visits using the subjective and objective measures and clinical assistants will be blinded as to the treatment type. Physician-based assessment of functional outcome with be assessed using the Disability of the Arm, Shoulder and Hand (DASH) score and Mayo Wrist scores, as well as independent assessment of DRUJ instability, ROM, and grip strength. Patient-based assessment will include visual analog pain scores as well as satisfaction questionnaires.
Primary pigmented nodular adrenocortical disease (PPNAD) is a pituitary-independent, primary adrenal form of hypercortisolism characterized by (a) resistance to suppression by dexamethasone and abolition of the normal diurnal rhythm of cortisol secretion, and (b) distinctive, bilateral, histopathologic changes of the adrenal glands, such as the formation of variably sized, pigmented nodular adenomas, loss of normal zonation and atrophy of the extranodular cortex. PPNAD can be associated with a variety of other manifestations, such as myxomas of the skin, heart, breast and other sites, psammomatous melanotic swannomas involving the peripheral nervous system (PNS), lentigines and blue nevi of the skin and mucosae, growth hormone (GH)-producing adenomas of the pituitary, testicular Sertoli cell tumors, and possibly other neoplasms (adrenocortical and thyroid follicular carcinoma, and ovarian cysts). These associations constitute a distinct clinical syndrome, Carney complex, a genetic syndrome. At present, there are no standardized screening tests for the members of families with affected individuals and the molecular mechanism(s) of this hereditary single and/or multiple neoplasia syndrome have not been completely elucidated (e.g. patients who meet clinical criteria for Carney complex but test negative for PRKAR1A mutation . This study seeks to define the genetic basis of PPNAD and/or Carney complex in sporadic and familial cases and the molecular pathogenesis of their tumors, to identify the carriers of the familial forms of the disease, and to determine the prognosis for carriers and affected individuals. The methods include standard clinical testing for endocrine and nonendocrine pathologic conditions of the subjects of the study, linkage analysis with DNA markers from areas of the genome likely to harbor the responsible gene(s), and finally genetic screening of these genes. Molecular studies of the tumors of the patients will provide additional clues for the pathophysiologic mechanisms leading to PPNAD/Carney complex. The study will ultimately provide sufficient data for genetic counseling of families with PPNAD and/or Carney complex, and, ultimately, the means for genetic screening and prenatal testing.
Patients without a history of COVID-19. This group consists of patients who have been diagnosed with stable angina but have no history of COVID-19 infection. This group serves as a comparison group to assess the potential impact of severe COVID-19 infection on coronary microvascular dysfunction in patients with stable angina.
The invention belongs to a traditional Chinese medicine, particularly relates to a traditional Chinese medicine for treating periodontal abscess. The invention is characterized in that the traditional Chinese medicine is composed of the following components in parts by weight: 5-9g of mulberry leaf, 5-15g of honeysuckle flower, 7-11g of Baikal skullcap root, 3-7g of borneol and 3-7g of pepper. The components are cleaned, aired, ground into fine powder, and mixed uniformly. The traditional Chinese medicine is decocted with clear water, and taken 1 dose a day, and every dose is taken by two times. The patient can recover within 5-10 days. The invention is on the basis of the traditional Chinese medicine authentication theory, has the advantages of simple formula, accessible materials, low cost, high curative effect and no toxic or side effect, and effectively treats periodontal abscess.
Lumbar spinal stabilization exercises will be given. Lumbar spinal stabilization exercises; diaphragmatic breathing, and contraction of the transversus abdominis and multifidus muscles will be taught in the supine position. Activation of these muscles will be studied in different positions (prone, crawling, sitting, and sitting on different surfaces). The focus will be on increasing kinesthetic awareness. It will be desirable to ensure and maintain the activation of these muscles during subsequent exercises. Exercises will be continued according to the patient's functional status and individual needs. Advancement of exercises; extremity movements on dynamic surfaces, narrowing of support surfaces, reciprocal movements, increasing the number of resistance and repetitions. The duration of a session will be 40 minutes.
FIELD: organic chemistry, biochemistry, pharmacy. SUBSTANCE: invention relates to derivatives of sulfonylamino acid and sulfonylaminohydroxaminic acid of the formula (I)  , their pharmaceutically acceptable salts where W represents OH or NHOH; X means: a) heterocyclic radical taken among group including imidazolinyl, dihydrobenzoisothiazolyl and so on; b) -NR 1 SO 2 R 2 , where R 1  means hydrogen atom; R 2  means unsubstituted phenylalkyl and so on; Y means carbon or sulfur atom under condition that when Y means carbon atom then n = 2; Z means phenyl optionally substituted with halogen atom, unsubstituted alkoxy- group, phenyloxy-group optionally substituted with halogen atom, unsubstituted alkoxy-group, phenyloxy- group optionally substituted with halogen atom, phenyloxyimidazolyl, 4-methylpiperazinyl, 4-phenyl- piperidinyl, pyridinyloxy-group,   where   means hydrogen atom;   means phenyl optionally substituted with hydroxy-group or phenyl, pyridinyl substituted with -CF 3 ; m means a whole number from 1 to 4; n means a whole number 1 or 2. Invention relates also to method for preparing compound of the formula (I) by interaction of compound of the formula (IV)   with compound of the formula (V)   to yield compound of the formula (VI)   that is converted to compound of the formula (I). Invention relates also to pharmaceutical composition inhibiting activity of metalloproteinase decomposing matrix that comprises effective amount of compound of the formula (I) and one or some pharmaceutically acceptable carriers. Invention provides the development of novel sulfonylamino-derivative inhibiting activity of metalloproteinase decomposing matrix. EFFECT: valuable biochemical properties of compounds. 9 cl, 2 tbl
Group 1 (solid tumor or lymphoma patients): Patients receive oral SAHA once daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients may be treated at the MTD.
BACKGROUND Ankylosing spondylitis (AS), a chronic inflammatory disease predominantly causing back pain, affects up to 0.5% of the global population, more commonly in males. Frequently undiagnosed in early stages, AS is often associated with comorbid depression and anxiety, imposing significant healthcare burdens. Despite available pharmaceutical treatments, exercise therapy (ET) has emerged as an effective, side-effect-free alternative, particularly for managing AS-induced back pain. This study aims to explore the research trends in ET for treating AS back pain from 2004-2023. MATERIAL AND METHODS A comprehensive analysis of 437 articles, sourced from the Science Citation Index-Expanded within the Web of Science Core Collection, was conducted using CiteSpace 6.2.R5. This study spanned from 2004 to October 15, 2023, examining publications, authors, institutions, and keywords to assess keyword co-occurrences, temporal progressions, and citation bursts. RESULTS Research interest in ET for AS began escalating around 2008 and has since shown steady growth. The USA emerged as a significant contributor, with Van der Heijde, Desiree, and RUDWALEIT M being notable authors. Key institutions include Assistance Publique Hopitaux Paris and UDICE-French Research Universities, with ANN RHEUM DIS being the most influential journal. The field's evolution is marked by interdisciplinary integration and branching into various sub-disciplines. CONCLUSIONS Exercise therapy for AS-induced back pain is a growing research area, necessitating further exploration in clinical management and rehabilitation strategies. The relationship between ET and osteoimmunological mechanisms remains a focal point for future research, with a trend towards personalized and interdisciplinary treatment approaches.
The detrimental effects of elevated intra-abdominal compartment pressure have been known for some time and are actively managed by most surgical critical care physicians. Similarly, it is well known that occasionally the abdomen cannot be immediately closed in some patients due to concern of elevated intra-abdominal pressure or ongoing contamination; these patients typically stay in hospital, often in expensive ICU's until final closure - and even then, some patients do not get definitive reconstruction of the abdominal wall until many months later, again adding to the expense of their care. Thus, there has been a move to give these patients early, aggressive closure of the abdomen, often using a combination of negative pressure wound therapy and biologic mesh. Currently these groups of patients who have early aggressive closure are incompletely studied; although abdominal compartment pressure measurements are routinely made on them, this is not commonly done intra-operatively when closure is being performed; nor have these patients been studied with continuous monitoring. This is especially striking considering the occlusive nature of negative wound therapy dressings: anecdotal increases in abdominal pressures have been noted in these patients, sometimes to dangerous levels. As there is accumulating evidence that diligent management of intra-abdominal pressure can improve outcomes in a variety of patients, there is an opportunity to apply accurate monitoring to a patient group that is also likely to benefit.

The investigators propose a prospective observational study on patients who are unable to be definitively closed at the time of surgery and are candidates for early aggressive abdominal closure. The investigators will monitor abdominal pressure using the AbViser continuous abdominal pressure monitoring device to ascertain whether there are episodes if intra-abdominal hypertension in these patients, and whether this improves or not after definitive closure. The research team will then attempt to correlate abdominal pressure measurements to outcomes. Finally the team will compare patients to historical controls using propensity scoring to explore differences in outcome.

Intra-abdominal pressure monitoring will be initiated when a patient has been identified as requiring an open abdomen. The monitoring will be done until the patient's abdominal wound has been closed and there are no elevated measurements. Once the patient has been discharged from the intensive care unit, the AbViser system will be discontinued. Patients will continue to be followed for the duration of their hospital stay and outcome measures will be assessed until discharge from the hospital, an expected average of 2 - 3 weeks.
Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m\^2). Post-transplant maintenance therapy is then prescribed if appropriate.
Water stress, a significant abiotic stressor, significantly hampers crop growth and yield, posing threat to food security. Despite the promising potential of nanoparticles (NPs) in enhancing plant stress tolerance, the precise mechanisms underlying the alleviation of water stress using O-Carboxymethyl chitosan nanoparticles (O-CMC-NPs) in maize remain elusive. In this study, we synthesized O-CMC-NPs and delved into their capacity to mitigate water stress (waterlogging and drought) in maize seedlings. Structural characterization revealed spherical O-CMC-NPs with a size of approximately 200 nm. These NPs accumulated near the seed embryo and root tip, resulting in a substantial increase in fresh and dry weights. The application of O-CMC-NPs to water-stressed maize seedlings remarkedly elevated the chlorophyll content and activity of various antioxidant enzymes, including superoxide dismutase (SOD), catalase (CAT), peroxidase (POD), and polyphenol oxidase (PPO). The malondialdehyde (MDA) content was significantly reduced compared to the untreated control. Additionally, the expression of stress-responsive genes, such as ZmSOD, ZmCAT, ZmPOD, ZmTIFY, ZmACO, ZmPYL2, ZmNF-YC12, and ZmEREB180, were significantly upregulated in the O-CMC-NPs treated seedlings. These findings unveil the novel role of O-CMC-NPs in enhancing plant stress tolerance, suggesting their potential application in safeguarding maize seedlings under water stress conditions and facilitating the recovery from oxidative damage.
Spasticity is a motor disorder characterized by a velocity-dependent increase in tonic stretch reflex due to upper motor neuron lesion. The prevalence of post-stroke spasticity is between 17-40%. In the assessment of spasticity, although biomechanical and neurophysiological methods provide quantitative data, semi-quantitative methods are mostly used clinically. The most frequently used spasticity measures are the Modified Ashworth Scale and the Modified Tardieu Scale. However, these methods have significant disadvantages. Therefore, the search for more reliable clinical measures continues. One of the newly developed clinical scales is called the Australian Spasticity Assessment Scale (ASAS). Although ASAS has been reported to have a high level of reliability in children with cerebral palsy, the same has not been detected in adult patients with acquired brain damage. The low number of patients and the heterogeneous study population have been reported as two of the important limitations in the reliability study of this measure.

In this study, researchers aim to investigate the inter-rater reliability of the ASAS in a study population consisting of a larger and more homogeneous patient population (those with post-stroke spasticity).
<P>PROBLEM TO BE SOLVED: To provide an external preparation for skin, excellent in a moisture retainability-imparting force in an extent for improving wrinkles.  <P>SOLUTION: This external preparation for the skin is characterized by containing (1) amodimethicone and (2) a polyethylene glycerol in a mass ratio of amodimethicone to polyethylene glycerol of 10:1 to 1:1. The emulsifier form is preferably an oil-in-water type emulsifier form. It is further preferable that the external preparation for the skin contains an alkyl-modified carboxyvinyl polymer and/or its salt, and ubidecarenone and/or α-lipoic acid. The ubidecarenone is preferably contained in the form of vesicle. It is preferable that the vesicle contains a hydrogenated phospholipid and phytosterol in addition to the ubidecarenone.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The present invention provides a asiaticoside antiadhesion film. It is a film preparation formed from centella total glycoside and sodium hyaluronate. The Chinese medicine centella total glycoside selected by said invention can effectively prevent postoperative adhesion and the sodium hyaluronate with excellent elasticity, lburication and osmosis is used as carrier skeleton. Said invention antiadhesion film can be better adhered on the opening of wound. Its therapeutic effect is good, and its cost is low. Said invention also provides its preparation method.
This invention relates to methods for detecting, identifying and quantifying enzymes, for example, human proteolytic enzymes. The method broadly comprises forming an immobilized or insoluble complex comprising enzyme, enzyme inhibitor and enzyme inhibitor-antibody reactive site and then detecting and identifying, preferably quantitatively, one or more enzymes bound to the complex. In a preferrend embodiment, a matrix, e.g. solid or semisolid surface or permeable matrix, has affixed thereto enzyme inhibitor-antibody or an immunologically active (inhibitor binding) fragment of such an antibody. This insoluble enzyme inhibitor interacting matrix is then contacted with biological fluid, e.g. body fluid, to bind one or more predetermined enzyme inhibitor-enzyme complexes, if present in the biological fluid. The bound enzyme is then detected, identified and preferably quantified.
A new recombinant antibody that targets transmembrane enzyme carbonic anhydrase XII was produced. The expression of the enzyme increases in certain types of cancer cells. Recombinant antibody produced is a new protein, which so far has not been described in scientific literature. First, cell line (hybridomas) producing monoclonal antibody to carbonic anhydrase XII was developed. Copy DNA sequences encoding an immunoglobulin variable regions were cloned from hybridoma cells, recombinant plasmids were created and recombinant antibody expression was attained. Well-known methods, such as hybridoma technology, genetic engineering, protein purification, immunochemical analysis were used for antibody development. Recombinant antibody produced may be applied in medical and biopharmaceutical branches due to capacity to inhibit growing of cancer cells containing carbonic anhydrase XII.
The invention relates to a colloid mask with a local carrier and a making method thereof. The colloid mask contains a colloid layer and a carrier layer. The colloid layer is formed by the use of high-water-absorption colloidal membrane materials (such as seaweed gel, high polymer gel, bio-fiber and the like) containing a liquid formulation such as a liquid formulation for beauty treatment and is used for energy supply. The colloid layer has a first side and an opposite second side, wherein the first side is used for covering the face of a user so as to make the liquid formulation to be contacted with the face skin. The carrier layer covers and combines on at least a local part, such as an eye, nose or mouse easily-cracking part, of the second side of the colloid layer so as to supply energy to enhance mechanical strength of the local part. However, part of area on the second side of the colloid layer is still reserved and not covered by the colloid layer in order to reduce material cost of the carrier layer. The carrier layer is formed by the use of knitted fabric such as lace fabric, spun yarn fabric and jacquard cloth, or is formed by the use of non-woven fabric, and patterns or marks can be preset on the carrier according to needs.
The present invention relates to a cosmetic composition such as lotion, skin, cream, or essence. More specifically, an extract of an alcohol-fermented wild cultivated ginseng, a leachate of an alcohol-fermented wild cultivated ginseng, and extract powder of an alcohol-fermented wild cultivated ginseng are mixed with various cosmetic composition ingredients instead of conventional distilled water. Therefore, cream, lotion, skin, or essence can be made from a mixed raw material at a mixing ratio. An extract of an alcohol-fermented wild cultivated ginseng, a leachate of an alcohol-fermented wild cultivated ginseng, and extract powder of an alcohol-fermented wild cultivated ginseng are mixed and used without using conventional distilled water at all. Therefore, it is possible to expect excellent antioxidant activities and skin anti-aging effects due to active ingredients thereof. It is possible to expect effects of preventing skin aging, soothing skin, and preventing decomposition of cosmetics. The use life of can be extended by inhibiting acidification and bacterial breeding. Various kinds of cosmetics such as skin, lotion, cream, or essence may be produced. Along with unique effects of various cosmetic products, the present invention can obtain various beneficial effects by sufficiently absorbing effective ingredients by a wild cultivated ginseng.
We may encounter patients with chronic empyema for whom open-window thoracostomy is unavoidable. However, patients with chronic empyema are sometimes at high-risk for surgery under general anesthesia. We, herein, present our surgical experience with three chronic empyema cases who underwent open-window thoracostomy under local anesthesia. Indications for open-window thoracostomy under local anesthesia were raised PaCO2 in Case 1, old age and poor performance status in Case 2, and a history of esophageal reconstruction and vocal cordoplasty in Case 3. All patients were well during the surgery. Case 1 developed type 2 respiratory failure postoperatively and had to be put on a ventilator, but finally recuperated. The sedatives used could have exacerbated raised PaCO2 in this patient, and careful selection of anesthetic agents is mandatory. Considering pain and stress that patients suffer during open-window thoracostomy under local anesthesia, case selection is necessary. Nevertheless, we believe that open-window thoracostomy under local anesthesia is an effective option for high-risk patients.
Sepsis is an extremely dangerous medical condition that emanates from the body's response to a pre-existing infection. Early detection of sepsis-inducing bacterial infections can greatly enhance the treatment process and potentially prevent the onset of sepsis. However, current point-of-care (POC) sensors are often complex and costly or lack the ideal sensitivity for effective bacterial detection. Therefore, it is crucial to develop rapid and sensitive biosensors for the on-site detection of sepsis-inducing bacteria. Herein, we developed a graphene oxide CRISPR-Cas12a (GO-CRISPR) biosensor for the detection of sepsis-inducing bacteria in human serum. In this strategy, single-stranded (ssDNA) FAM probes were quenched with single-layer graphene oxide (GO). Target-activated Cas12a trans-cleavage was utilized for the degradation of the ssDNA probes, detaching the short ssDNA probes from GO and recovering the fluorescent signals. Under optimal conditions, we employed our GO-CRISPR system for the detection of Salmonella Typhimurium (S. Typhimurium) with a detection sensitivity of as low as 3 × 103 CFU/mL in human serum, as well as a good detection specificity toward other competing bacteria. In addition, the GO-CRISPR biosensor exhibited excellent sensitivity to the detection of S. Typhimurium in spiked human serum. The GO-CRISPR system offers superior rapidity for the detection of sepsis-inducing bacteria and has the potential to enhance the early detection of bacterial infections in resource-limited settings, expediting the response for patients at risk of sepsis.